...Domainex and Imperial partnered to discover therapies to treat myocardial infarction. Domainex will provide biochemical and... ...The companies did not respond in time for publication. Imperial College London , London, U.K. Domainex Ltd....
...Auspherix Ltd. (Stevenage, U.K.) (formerly Auspherix Pty. Ltd.) and Domainex extended a research contract through 2017... ...addition to advancing additional compounds under the deal. Auspherix said at least five chemists at Domainex... ...companies develop. Auspherix declined to provide financial terms, and Domainex did not respond to inquiries. Domainex Ltd....
...Academic Research (STAR) award to support academic groups in the early stages of drug discovery. Domainex... ...biochemical screening assay is in place and what makes the potential drug discovery project novel. Domainex Ltd....
...Horizon and Domainex partnered to develop Domainex's TANK-binding kinase 1 (TBK1) and inhibitor of kappa light... ...research program. Horizon will use its X-MAN isogenic disease model human cell lines to profile Domainex's... ...includes precision rAAV-mediated genome editing and 2D and 3D phenotypic assays. Details were not disclosed. Domainex...
...The partners extended by an undisclosed time a 2003 deal for Domainex to use its LeadBuilder... ...for compound identified. Further terms were not disclosed. Ark Therapeutics Group plc (LSE:AKT), London, U.K. Domainex Ltd....
...light polypeptide gene enhancer in B cells kinase epsilon (IKBKE) (IKK-i) to treat breast cancer. Domainex... ...through proof of concept before the partners seek out-licensing for compounds developed from both targets. Domainex... ...will have an undisclosed financial share in the others IP. Further terms were not disclosed. Domainex Ltd....
...Domainex and Imperial partnered to discover therapies to treat myocardial infarction. Domainex will provide biochemical and... ...The companies did not respond in time for publication. Imperial College London , London, U.K. Domainex Ltd....
...Auspherix Ltd. (Stevenage, U.K.) (formerly Auspherix Pty. Ltd.) and Domainex extended a research contract through 2017... ...addition to advancing additional compounds under the deal. Auspherix said at least five chemists at Domainex... ...companies develop. Auspherix declined to provide financial terms, and Domainex did not respond to inquiries. Domainex Ltd....
...Academic Research (STAR) award to support academic groups in the early stages of drug discovery. Domainex... ...biochemical screening assay is in place and what makes the potential drug discovery project novel. Domainex Ltd....
...Horizon and Domainex partnered to develop Domainex's TANK-binding kinase 1 (TBK1) and inhibitor of kappa light... ...research program. Horizon will use its X-MAN isogenic disease model human cell lines to profile Domainex's... ...includes precision rAAV-mediated genome editing and 2D and 3D phenotypic assays. Details were not disclosed. Domainex...
...The partners extended by an undisclosed time a 2003 deal for Domainex to use its LeadBuilder... ...for compound identified. Further terms were not disclosed. Ark Therapeutics Group plc (LSE:AKT), London, U.K. Domainex Ltd....
...light polypeptide gene enhancer in B cells kinase epsilon (IKBKE) (IKK-i) to treat breast cancer. Domainex... ...through proof of concept before the partners seek out-licensing for compounds developed from both targets. Domainex... ...will have an undisclosed financial share in the others IP. Further terms were not disclosed. Domainex Ltd....
